. At a molecular level, this mechanism ultimately depends on the interaction between the liganded VDR and a specific vitamin D response element within the proximal promoter of the cathelicidin gene (6 -8) , but, in vivo, other factors are likely to be involved. In particular, we have shown that induction of monocyte cathelicidin is highly dependent on the initial component of the intracrine vitamin D pathway, namely the availability of substrate for CYP27b1, 25OHD (2, 3) . Serum levels of 25OHD vary considerably within humans and provide the best circulating marker for vitamin D status (9) . As such, serum 25OHD is likely to be a key determinant of vitamin D-mediated immune activity, particularly for individuals who are vitamin D (25OHD) insufficient or deficient (10, 11) .
A key factor in regulating the availability of 25OHD to cells is the serum vitamin D-binding protein (DBP), also known as group-specific component (Gc). DBP is an abundant multifunctional protein structurally related to albumin and ␣-fetoprotein (12, 13) . Almost all vitamin D metabolites circulate bound to either DBP (high affinity for vitamin D ligands) or serum albumin (high abundance but low affinity for vitamin D ligands). In the proximal tubule of the kidney (14) and in mammary cells (15) , delivery of substrate 25OHD to CYP27b1 occurs through megalin/ cubilin-mediated endocytosis of this metabolite bound to DBP (16) . However, as yet, it is unclear whether such a mechanism is crucial for synthesis of 1,25(OH) 2 D in other cells expressing CYP27b1. We have therefore characterized the effects of DBP on vitamin D-induced cathelicidin in monocytes and the extent to which this may be influenced by DBP gene variants.
Materials and Methods

Cell culture
Ficoll-isolated peripheral blood mononuclear cells (PBMCs) derived from anonymous healthy donors (screened in accordance with standard transfusion medicine protocols) were obtained from the Center for AIDS 
Quantitative real-time PCR
RNA was isolated by Trizol (Invitrogen) extraction and cDNA synthesized by SuperScript reverse transcriptase III (Invitrogen) according to the manufacturer's protocol using random hexamers as previously described (2) . Quantitative PCR analysis was performed on a Stratagene MX-3005P instrument using TaqMan reagents from Applied Biosystems (Foster City, CA). Specifically, we used FAM-labeled TaqMan gene expression assay probe/primer sets Hs00167999_m1 (CYP24A1) and Hs00189038_m1 (cathelicidin) in conjunction with VIC/MGB probe/primer for 18S rRNA (endogenous control) (part 4319413E). All cDNAs were amplified under the following conditions: 50 C for 2 min and then 95 C for 10 min followed by 45 cycles of 95 C for 15 sec and 60 C for 1 min. All reactions were performed in triplicate and reported as difference in cycle threshold (⌬⌬Ct) values (⌬Ct value for vehicle-treated control Ϫ ⌬Ct for treated sample).
Fluorescent tagging of DBP
One milligram of human Gc-globulin (Calbiochem) was fluorescently tagged using Alexa-Fluor 488 protein labeling kit (catalog item A-10235; Molecular Probes/Invitrogen, Carlsbad, CA) reagents for 30 min at room temperature and separated from free dye through size exclusion resin provided with the kit according to manufacturer's instructions. The resulting fluorescently labeled DBP is referred to as Alexa-DBP. 
25OHD 3 -DBP-binding assays
Flow cytometric analysis of DBP cellular uptake
PBMCs (2.5 ϫ 10 6 ) were added to 24-well plates in RPMI containing 1% FBS and incubated for 2 h, and nonadherent cells were aspirated to enrich for monocytes. Cells were cultured with RPMI plus 10% FBS plus granulocyte-macrophage colony-stimulating factor (10 U/ml) and then washed with SF RPMI. Parallel cultures of megalin-positive BN16 cells were also used. Both types of cell were pretreated with 0.4 M receptor-associated protein (RAP) (Calbiochem), a megalin-cubilin antagonist for 15 min. Aliquots of Alexa-DBP (0.4 or 0.1 M in RAP antagonist studies) were added to cells in SF RPMI and incubated for 15 min at 37 C. Cells were then placed on ice for 5 min, IgG-R-phycoerythrin isotype control or CD14-R-phycoerythrin (Caltag/ Invitrogen, Carlsbad, CA) was added and incubated for 10 min on ice. The cells were then washed with ice-cold PBS, removed from culture wells by scraping in ice-cold PBS, collected by centrifugation, washed again in ice-cold PBS, and then fixed with 4% paraformaldehyde in PBS (pH 7.4). Flow cytometric analysis was carried out using a Beckman Coulter (Brea, CA) Cyan ADP with Summit 4.3 software.
DBP genotype (Gc) analysis
Twenty age-matched (30 -39 yr) and sex-matched (male) human serum samples from Black and white donors were purchased from a commercial source (Innovative Research), and 16 donor serum samples from uninfected patients of Gujarati ethnicity were obtained from Dr. Martineau's United Kingdom clinic, the latter in accordance with local ethical approval. Allelic forms of DBP were determined by DNA sequencing (18) or by serum isoelectric focusing as described previously (19) .
Statistical analyses
Data are expressed as mean Ϯ SD unless otherwise stated. Statistical analysis of dose response and single treatment was determined by two-tailed unpaired equal-variance Student's t test. Statistical analysis of variations between sera with different DBP genotypes treatment studies was carried out by Kruskal-Wallis one-way ANOVA with the Dunn method as a post hoc multiple-comparison procedure applied to raw ⌬Ct values from RT-PCR assays (Sigmaplot 9.0 software; Systat Inc., San Jose, CA).
Results
DBP attenuates 25OHD 3 -and 1,25(OH) 2 D 3 -induced cathelicidin expression in monocytes
Initial experiments were carried out to determine whether monocyte responses to vitamin D metabolites are influenced by DBP. Data in We have reported previously that even in the absence of treatments known to induce CYP27b1 such as TLR ligands (2, 3) or IL-15 (4), monocytes at day 1 of culture exhibit baseline conversion of 25OHD 3 to 1,25(OH) 2 D 3 which can act in an intracrine fashion to induce expression of genes such as cathelicidin (2) . Thus, in the current study, cells were cultured without added immune activators to minimize confounding effects that might influence responses to DBP and vitamin D metabolites. However, in a series of parallel experiments we showed that suppression of 25OHD 3 action by DBP was also observed in monocytes cultured for up to ten days to generate a more macrophage-like phenotype (Supplemental Fig. 1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org), and in monocytes treated with IL-15 to stimulate CYP27b1 expression (Supplemental Fig. 2 ).
Internalization of DBP by human monocytes
Previous reports have shown that DBP can be internalized by cells via a megalin-mediated endocytic pathway in kidney (14) and mammary (15) (Fig. 3A ). Alexa-DBP was then incubated with monocytes and uptake assessed by fluorescent microscopy ( Fig. 3B ) and flow cytometry (Fig. 3 , C-E). Microscopy indicated that Alexa-DBP was internalized by monocytes in a similar fashion to megalin-positive BN16 cells, (Fig. 3B) . To demonstrate similar cytosolic patterns of DBP expression in the two cell lines, longer exposure times were required for monocytes, indicating higher levels of DBP uptake in BN16 cells. This was further underlined by flow cytometric analyses that showed higher mean fluorescence intensity for BN16 cells (Fig. 3D , middle panel) compared with monocytes (Fig.  3E, middle panel) . Nevertheless, measurable uptake of Alexa-DBP was detectable in CD14-positive monocytes at both d 1 and 7 of culture (Fig. 3C) . To determine whether this uptake was mediated via megalin, cells were preincubated with RAP, a megalin antagonist. RAP reduced Alexa-DBP uptake in BN16 cells (Fig. 3D ) but had no effect on Alexa-DBP uptake in monocytes (Fig. 3E) . In additional studies, RT-PCR analysis revealed no significant mRNA expression for either megalin or its coreceptor cubulin in monocytic cells (data not shown).
Induction of monocyte cathelicidin by 25OHD 3 varies with DBP genotype
Having demonstrated the importance of DBP as a determinant of vitamin D-induced responses in monocytes, we then sought to determine whether established genetic differences in DBP provide an additional level of variation to this effect. To assess the impact of DBP gene variants on 25OHD 3 -induced cathelicidin, monocytes were cultured in medium containing 5% human serum from donors with the six different combinations of the three major allelic variants of DBP: Gc1F, Gc1S, and Gc2. Initial dose-response studies showed more sensitive responses to 25OHD 3 using serum from Gc2-1S donors compared with those with the Gc1F-1F genotype (Fig. 4) .
Further analysis by ANOVA of combinations of Gc alleles using 36 serum samples from donors with different ethnic backgrounds confirmed a statistically significant (P ϭ 0.01) increase in cathelicidin induction after treatment with a single dose of 25OHD 3 in monocytes cultured with Gc2-1S (P ϭ 0.003) or Gc2-2 (P ϭ 0.016) serum compared with Gc1F-1F serum (Table 1) . Indeed, a straightforward comparison between donors with least one allele of Gc1F (Gc1F-1F, Gc1F-1S, and Gc1F-2) and those without Gc1F (Gc1S-1S and Gc2-1S, and Gc2-2) showed that monocytes cultured in the latter were 1.97-fold more sensitive to 25OHD 3 (P ϭ 0.002). Likewise, cells cultured in serum from donors with at least one Gc2 allele showed 1.73-fold higher sensitivity to 25OHD 3 than cells cultured in serum from donors without a Gc2 allele (P ϭ 0.011). Analysis of a subset of the sera revealed no statistical difference in levels of 25OHD or 1,25(OH) 2 D between donors with different Gc types (Supplemental Table 1 ).
Discussion
Serum levels of 25OHD vary considerably within humans and provide the best circulating marker for vitamin D status (9) . As such, serum 25OHD is likely to be a key determinant of many vitamin D functions, notably its antibacterial effects, which are known to be mediated via intracrine/autocrine mechanisms (2, 3). However, we hypothesized that biological responses to 25OHD will also be strongly influenced by serum proteins that bind vitamin D metabolites, in particular DBP. In data presented here, we confirm that DBP plays a pivotal role in modulating monocyte responses to 25OHD 3 and In serum, vitamin D metabolites bind primarily to DBP but may also associate with other abundant circulating proteins such as albumin. The affinity of albumin for 25OHD 3 
is substantially lower than that observed for DBP and 25OHD 3 (23, 24) . However, because of the relative abundance of albumin in serum (650 M) compared with DBP (5 M), the potential remains for some vitamin D metabolites to be transported in the circulation by albumin. Despite this, it is generally assumed that vitamin D metabolites are biologically active when unbound, even though this fraction is likely to be very small (24, 25) . Indeed, the free-hormone hypothesis has been proposed as a general mechanism for the cellular uptake of steroid-like molecules because they are highly lipophilic and therefore have the potential to passively diffuse across cell membranes (26, 27) . The concentrations of 25OHD 3 and 1,25(OH) 2 D 3 used in the current study were chosen to represent physiological to supraphysiological levels of these metabolites (9) . Under such conditions, one would predict that the proportion of free (relative to DBP-bound) will be greater for 1,25(OH) 2 D 3 than 25OHD 3 . This is endorsed by data in Figs. 1 and 2 showing that DBP is less effective at attenuating monocyte responses to 1,25(OH) 2 D 3 and provides further support for the free-hormone hypothesis.
The free-hormone hypothesis is not universal. For some cell types such as renal proximal tubule cells (14, 16) and breast epithelial cells (15, 28) , uptake of 25OHD, and subsequent conversion to 1,25(OH) 2 D, has been shown to involve endocytosis of DBP mediated via the megalin and cubilin receptors. Flow cytometry suggests that monocytes are also able to internalize DBP (see Fig. 3 ). However, the magnitude of this uptake was relatively low when compared with cells known to express megalin and cubilin. Moreover, we were unable to detect transcripts for megalin/cubilin in monocytes (data not shown), and inhibition of these receptors using RAP had no effect on monocyte uptake of DBP. The functional significance of non-megalin-mediated DBP uptake by monocytes is unclear but may be related to the alternative function of DBP as an actinbinding protein (29) . This facet of DBP has been shown to be a highly effective mechanism for disrupting the intracellular translocation of infectious agents such as Listeria monocytogenes, which occurs via hijack of host actin filaments (30) . DBP can also act as a macrophage-activating factor (Maf) precursor after posttranslational modification involving glycosidase enzymes found in T and B cells (31) . Although DBP-Maf has been reported to act as a pluripotent cytokine affecting a variety of biological systems (32) (33) (34) , these effects do not appear to be influenced by binding of vitamin D metabolites. A key feature of DBP is that polymorphic variants of this protein were first described as long ago as 1959 (35) . The ancestral DBP allele, Gc1F, has undergone two amino acid changes: a D416E change to form Gc1S and a T420K change to form Gc2 (see Fig. 5 ). These alterations in amino acid sequence have been shown to affect the affinity of DBP for vitamin D ligands. The reported K d values for 25OHD 3 with Gc1F ϭ 0.9 nM, with Gc1S ϭ 1.7 nM, and with Gc2 ϭ 2.8 nM (22) . Similar K d variations have also been reported for 1,25(OH) 2 D 3 : Gc1F ϭ 56 nM, Gc1S ϭ 160 nM, and Gc2 ϭ 240 nM (22) . Gc alleles have also been linked to varying concentrations of DBP in serum, with Gc2 being the least abundant and Gc1F exhibiting the highest levels (19) . It was therefore interesting to observe that the DBP genotype with the highest affinity/abundance (Gc1F-1F allelic combination) exhibited a significantly weaker cathelicidin response to 25OHD 3 than the low-affinity/abundance Gc2-1S genotype (Table 1 and Fig. 4) . This contrasts the endocrine function of the DBP variants, where Gc1F-1F is better able to maintain serum levels of vitamin D metabolites as a consequence of more efficient retention of 25OHD 3 and 1,25(OH) 2 D 3 after megalin-mediated uptake of DBP by kidney cells (36) .
Data presented here suggest that in humans, the ancestral form of DBP (Gc1F) has undergone loss-of-function amino acid changes that nevertheless confer important biological advantages with respect to the antibacterial actions of vitamin D. As outlined in Fig. 5 , alterations in DBP would have had little or no effect on vitamin D physiology under conditions of high serum 25OHD status. However, with lower levels of 25OHD, loss of the Gc1F allele would be advantageous with respect to improved induction of antimicrobial agents such as cathelicidin. Maintenance of vitamin D function is considered to have been a pivotal factor in the adaptive changes in skin pigmentation that occurred as early humans migrated toward Northern latitudes (37) . Under these conditions, individuals with darker skin pigmentation would have been less able to generate vitamin D via the epidermal action of UV light. As a consequence, early humans may have experienced a decline in serum 25OHD levels sufficient to compromise biological functions such as innate immune antibacterial activity. Kappelman and colleagues (38) have postulated that this may have been the underlying basis for their detection of tuberculosis infection in 500,000-yr-old hominid fossils discovered in Western Turkey. With this in mind, it is tempting to speculate that evolutionary changes in DBP may have occurred against a backdrop of increased bacterial infection and decreased vitamin D status as early humans migrated out of Africa.
Insufficient serum levels of 25OHD have been correlated with a wide range of detrimental health outcomes including infectious diseases (11, 39 -41) . However, data presented here suggest that the DBP genotype of individuals is also an important determinant of the bioavailability of vitamin D metabolites to key target cells such as monocytes. It is therefore interesting to note studies showing association between the Gc1F allele and increased risk of chronic obstructive pulmonary disease (42) and syphilis infection (43) . Paradoxically, a more recent study has linked the Gc2 allele with susceptibility to active tuberculosis (18) . There are several potential explanations for this. Notably, the Gc2 form of DBP lacks the threonine at amino acid 420 required for posttranslational modifica- tion of DBP to DBP-Maf. Individuals with a Gc2-2 genotype will thus be unable to exhibit this facet of DBP action, although the impact of this with respect to innate immune response to infection is unclear. It should also be noted that association between the Gc2-2 genotype and active tuberculosis was observed only for a specific cohort of Gujarati origin living in London, in which the mean serum levels of 25OHD were extremely low (approximately 20 nM). Moreover, the association was lost for those patients with 25OHD levels greater than 20 nM. With this in mind, it is interesting to note that in patients with chronic obstructive pulmonary disease, the Gc2-2 allelic combination has been linked to low serum 25OHD levels (44) . Thus, it is important to recognize that variations in DBP will affect both local (intracrine) and systemic (endocrine) actions of vitamin D. We therefore postulate that future studies of vitamin D and human disease will need to incorporate analysis of both serum vitamin D status and DBP genotype.
